Scarica l'app Stockscreener
52.17
0.56%
0.29
Dopo l'orario di chiusura:
52.08
-0.09
-0.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 3.2%What's Next? - MarketBeat
MoonLake Immunotherapeutics announces board change, incentive plan - Investing.com
MoonLake Immunotherapeutics Announces Board Changes and Incentives - TipRanks
MoonLake Immunotherapeutics announces board change, incentive plan By Investing.com - Investing.com UK
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 7.9%Here's What Happened - MarketBeat
We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate - Simply Wall St
Wellington Management Group LLP Cuts Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Trading (MLTX) With Integrated Risk Controls - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.6%What's Next? - MarketBeat
MoonLake Immunotherapeutics' SWOT analysis: stock outlook amid HS market potential - Investing.com
Clear Street sets $108 target on Moonlake Immunotherapeutics stock By Investing.com - Investing.com UK
Clear Street sets $108 target on Moonlake Immunotherapeutics stock - Investing.com
MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
When (MLTX) Moves Investors should Listen - Stock Traders Daily
Erste Asset Management GmbH Invests $741,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Fmr LLC Purchases 1,306,215 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Westfield Capital Management Co. LP Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
(MLTX) Technical Pivots with Risk Controls - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $79.00 Consensus PT from Brokerages - MarketBeat
MoonLake Immunotherapeutics: A Somewhat Complicated Story (NASDAQ:MLTX) - Seeking Alpha
Victory Capital Management Inc. Has $10.98 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MoonLake Immunotherapeutics management to meet with Oppenheimer - TipRanks
MoonLake Immunotherapeutics' (MLTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
MoonLake Immunotherapeutics' SWOT analysis: biopharma stock faces HS market potential, execution risks - Investing.com Canada
(MLTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
MoonLake Immunotherapeutics announces first patients screened in IZAR program - TipRanks
MoonLake Launches Major Phase 3 Trials for Psoriatic Arthritis Drug After Strong Phase 2 Results | MLTX Stock News - StockTitan
FMR LLC's Strategic Acquisition of MoonLake Immunotherapeutics S - GuruFocus.com
MoonLake Immunotherapeutics (MLTX) Quarterly 10-Q Report - Quartzy
MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Q3 Earnings Forecast for MLTX Issued By Wedbush - Defense World
What is Wedbush's Forecast for MLTX Q3 Earnings? - MarketBeat
MoonLake Immunotherapeutics reports Q3 EPS (56c), consensus (43c) - TipRanks
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire
MoonLake Reports $493.9M Cash Position, Advances Multiple Phase 3 Trials | MLTX Stock News - StockTitan
MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to "Strong-Buy" at Wedbush - MarketBeat
Wedbush Reiterates "Outperform" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
AlphaCentric Advisors LLC Invests $706,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by Harbor Capital Advisors Inc. - MarketBeat
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
75,469 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Acquired by Rice Hall James & Associates LLC - MarketBeat
MLTX Makes Notable Cross Below Critical Moving Average - Nasdaq
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.45 Average PT from Brokerages - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts - MSN
I'm Eyeing 2 Promising Biotech Plays as Oversold Market Gets Under My Skin - TheStreet
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):